<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394158</url>
  </required_header>
  <id_info>
    <org_study_id>14SM1971</org_study_id>
    <secondary_id>2014-001244-38</secondary_id>
    <nct_id>NCT02394158</nct_id>
  </id_info>
  <brief_title>Preventing Recurrent Gestational Diabetes With Metformin</brief_title>
  <acronym>PRoDroME</acronym>
  <official_title>Preventing Recurrent Gestational Diabetes Mellitus With Early Metformin Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London North West Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Novo Nordisk UK Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis: Intervention with metformin therapy early in pregnancy will prevent
      gestational diabetes mellitus recurring in previously affected pregnancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes mellitus (GDM) is a common medical complication of pregnancy and is
      associated with increased risks to mother and baby. The incidence is increasing reflecting
      changing pre-gravid female demographics. Once one pregnancy is complicated by GDM, subsequent
      pregnancies are more likely to be affected by the same condition. This reported risk of
      recurrence is estimated to range between 35 and 80%, with non-caucasian ethnicity being the
      strongest predictor of GDM recurrence. Evidence regarding further predictors of recurrent GDM
      is conflicting and measures that might prevent recurrence need exploring.

      Metformin is commonly used in the treatment of established GDM and has been shown to reduce
      the incidence of GDM in the context of polycystic ovarian syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Gestational Diabetes at any point during the course of pregnancy</measure>
    <time_frame>From 12 weeks pregnancy until the onset of labour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal gestational weight gain</measure>
    <time_frame>Difference between weight at 12 weeks gestation and 36 weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for insulin therapy</measure>
    <time_frame>From 12 weeks gestation until 36 weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum glucose levels</measure>
    <time_frame>6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of maternal physical and psychological health as assessed by questionnaires</measure>
    <time_frame>From 12 weeks gestation until 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal birthweight and birthweight centile</measure>
    <time_frame>At Birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of neonatal outcomes (neonatal hypoglycaemia requiring treatment, respiratory distress syndrome requiring oxygen therapy/ continuous positive airway pressure, neonatal hyperbilirubinaemia requiring phototherapy).</measure>
    <time_frame>At Birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness of the intervention</measure>
    <time_frame>From 12 weeks gestation until 6 weeks postpartum</time_frame>
    <description>Difference in requirement for medical services and unplanned hospital/ General Practitioner attendances between the two arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>From 12 weeks gestation until 6 weeks postpartum</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal triglyceride concentrations</measure>
    <time_frame>From 12 weeks gestation until 6 weeks postpartum</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fetal hyperinsulinaemia</measure>
    <time_frame>Delivery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention arm Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin (500mg tablets) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo tablets (500mg) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Intervention arm Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Control arm placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy;

          -  8-22 weeks gestation

          -  Previous pregnancy complicated by gestational diabetes

        Exclusion Criteria:

          -  Established pre-existing diabetes (including unrecognised diabetes defined as a
             fasting plasma glucose ≥ 7.0mmol/L and/ or HbA1c ≥ 48mmol/mol); Contraindications to
             metformin therapy (creatinine ≥ 130μmol/L/ alanine transaminase ≥ 2.0 x upper limit
             normal/ previous intolerance to metformin)

          -  Planned continued antenatal care/ delivery at centre not included in trial

          -  Planned fast for cultural/ religious reasons e.g. Ramadan
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Robinson, FRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Robinson, FRCP, MD</last_name>
    <phone>0203 312 1253</phone>
    <email>stephen.robinson@imperial.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rochan Agha-Jaffar, BMBS, MRCP</last_name>
    <phone>0207 594 6140</phone>
    <email>r.agha-jaffar@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Robinson, FRCP, MD</last_name>
      <phone>0203 312 1253</phone>
    </contact>
    <contact_backup>
      <last_name>Rochan Agha-Jaffar, BMBS, MRCP</last_name>
      <phone>0207 594 6140</phone>
      <email>r.agha-jaffar@imperial.ac.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>London North West Healthcare Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mushtaqur Rahman, FRCP, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Rochan Agha-Jaffar, BMBS, MRCP</last_name>
      <phone>0207 594 6140</phone>
      <email>r.agha-jaffar@imperial.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.</citation>
    <PMID>18463375</PMID>
  </reference>
  <reference>
    <citation>Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008 May 8;358(19):2003-15. doi: 10.1056/NEJMoa0707193. Erratum in: N Engl J Med. 2008 Jul 3;359(1):106.</citation>
    <PMID>18463376</PMID>
  </reference>
  <reference>
    <citation>Getahun D, Fassett MJ, Jacobsen SJ. Gestational diabetes: risk of recurrence in subsequent pregnancies. Am J Obstet Gynecol. 2010 Nov;203(5):467.e1-6. doi: 10.1016/j.ajog.2010.05.032. Epub 2010 Jul 13.</citation>
    <PMID>20630491</PMID>
  </reference>
  <reference>
    <citation>Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, Kunz R, Mol BW, Coomarasamy A, Khan KS. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ. 2012 May 16;344:e2088. doi: 10.1136/bmj.e2088.</citation>
    <PMID>22596383</PMID>
  </reference>
  <reference>
    <citation>De Leo V, Musacchio MC, Piomboni P, Di Sabatino A, Morgante G. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):63-6. doi: 10.1016/j.ejogrb.2011.03.024. Epub 2011 May 6.</citation>
    <PMID>21530058</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Gestational Diabetes Mellitus</keyword>
  <keyword>Prevention</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

